HAMBURG, GERMANY, AND TORONTO, ON / ACCESSWIRE / April 2, 2020 / Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809) and the innovative biotechnology company panCELLa Inc.

Made Scientific, Inc., a leading U.S.-based clinical- and commercial-stage cell therapy contract development and ...

iXCells Biotechnologies focuses on creating a broad portfolio of iPSC-derived off-the-shelf and custom cell models from healthy and patient donors to make "clinical-trials-in-a-plate" a reality SAN ...

MILPITAS, Calif.--(BUSINESS WIRE)--Applied StemCell, an advanced therapeutics CRO/CDMO specializing in iPSCs, gene editing, and small animal models, announced today that it has submitted a Type II ...

Evotec and Sernova announce exclusive strategic partnership for iPSC-based beta cell replacement therapy to advance a 'functional cure' for diabetes 17.05.2022 / 07:30 The issuer is solely responsible ...

In vitro data showcases CNTY-101’s ability to induce CD19-specific cytolysis of B-cells and potential to treat B-cell driven autoimmune diseases including systemic lupus erythematosus (SLE) ...

Many drugs still fail after promising preclinical results, raising difficult questions about how disease is modelled in the ...

LEVERKUSEN, Germany & PHILADELPHIA & TOKYO--(BUSINESS WIRE)--Century Therapeutics, which was created by Versant Ventures as part of the firm’s core strategy to launch innovative biotech companies, ...

The New York Blood Center Enterprises and the Chan Zuckerberg Biohub are collaborating to derive induced pluripotent stem cell lines from cord blood, using NYBCe’s inventory of over 30,000 units, ...

Century Therapeutics Presents New Preclinical Data Highlighting iPSC-derived Cell Therapy Platform Technology at the 2024 American Association for Cancer Research (AACR) Annual Meeting ...

ACQUIRED ASSETS FROM NCARDIA AG INCLUDE IP PORTFOLIO, IPSC-BASED CELLULAR PRODUCTS AND AN EXPERIENCED STEM CELL BIOLOGY TEAM EXPANSION OF IPSC DISCOVERY PLATFORM STRENGTHENS EVOTEC'S POSITION AS A ...

The presented data underscores the platform's ability to reprogram donor cells into iPSCs, expand them, and guide their differentiation into gamma-delta T cells through IN8bio's proprietary process, ...